OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy.
A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy profiles, warranting further investigation in a larger, controlled trial—MATRISS2.
The MATRISS2 study is a randomized, double-blind, placebo-controlled trial set to enroll 60 participants (30 receiving OTR4132 and 30 receiving placebo) across 15 stroke centers in France. The study aims to confirm the efficacy of a 2 mg dose of OTR4132-MD in patients with anterior ischemic stroke post-thrombectomy. Key endpoints include:
- NIHSS neurological score at 24 hours
- Rate of intracranial hemorrhages at 24 hours
- MRI lesion volume at 3 months
- Neurological scores at 3 months
For more details, visit the study reference: ClinicalTrials.gov (NCT06700824).
